1
|
|
2
|
Trottmann M, Marcon J, Pompe S, Strobach D, Becker A, Stief C. Konservative Therapie der erektilen Dysfunktion. Urologe A 2015; 54:668-75. [DOI: 10.1007/s00120-015-3794-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Sung HH, Ahn JS, Kim JJ, Choo SH, Han DH, Lee SW. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology 2013; 2:45-50. [DOI: 10.1111/j.2047-2927.2013.00155.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2013] [Revised: 09/24/2013] [Accepted: 10/08/2013] [Indexed: 12/26/2022]
Affiliation(s)
- H. H. Sung
- Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea
| | - J. S. Ahn
- Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea
| | - J. J. Kim
- Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea
| | - S. H. Choo
- Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea
| | - D. H. Han
- Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea
| | - S. W. Lee
- Department of Urology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea
| |
Collapse
|
4
|
Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE, Mulhall JP. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med 2013; 10:2559-65. [PMID: 23898886 DOI: 10.1111/jsm.12271] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Intracavernosal injection (ICI) therapy is a well-recognized treatment strategy with high success rates for men with erectile dysfunction. Despite this, injection anxiety and pain related to injection are significant barriers to its use. AIMS This study aims to examine injection anxiety and injection pain in patients using ICI. METHODS Men starting ICI therapy post radical pelvic surgery completed questionnaires at initial visit, at each of the two ICI training sessions and at a 4-month follow-up visit. MAIN OUTCOME MEASURES Injection Anxiety Scale, Injection Pain Scale, Injection Reaction Inventory, and the Erectile Function Domain of the International Index of Erectile Function. RESULTS Average age of the 68 men was 60±8 years. At 4 months, the self-reported frequency of ICI use was: 29%<1/week, 26% 1/week, 40% 2/week, and 5% 3/week. Mean injection anxiety score at first injection was 5.7±2.8 (range 0-10) and significantly decreased to a 4.1±3 at 4 months (P<0.001). At first injection, 65% reported high injection anxiety (≥5) and this significantly decreased to 42% (P=0.003) at 4 months. Anxiety at first injection was negatively related to ICI frequency at 4 months (r=-0.23, P=0.08). Mean injection pain score at first injection was low (2.2±1.8, range 0-10) and 59% rated injection pain≤2. Injection pain remained consistent across time periods. At first injection, injection anxiety (assessed prior to injection) was related to injection pain (r=0.21, P=0.04) and subjects (n=21) who reported high injection anxiety (≥5) across time points, reported an increase in injection pain scores from first injection to 4 months (2.7 vs. 3.7, P=0.05). CONCLUSIONS Although injection anxiety decreased with ICI use, mean injection anxiety remained at a moderate level (4.4) and 42% of men continued to report "high" injection anxiety at 4 months. While injection pain was low, injection anxiety and pain were related. These data suggest the need for a psychological intervention to help lower injection anxiety related to ICI.
Collapse
Affiliation(s)
- Christian J Nelson
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | |
Collapse
|
5
|
Prabhu V, Alukal JP, Laze J, Makarov DV, Lepor H. Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction. J Urol 2012; 189:238-42. [PMID: 23174252 DOI: 10.1016/j.juro.2012.08.089] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Indexed: 01/22/2023]
Abstract
PURPOSE Intracorporeal injections have low use rates and high discontinuation rates. We examined factors associated with intracorporeal injection use, long-term satisfaction with intracorporeal injection and reasons for discontinuation in men treated with radical prostatectomy. MATERIALS AND METHODS Between October 2000 and September 2003, 731 men who underwent open radical retropubic prostatectomy were enrolled in a prospective outcomes study. The 8-year followup evaluation included the UCLA-PCI, and a survey capturing intracorporeal injection use, satisfaction and reasons for discontinuation. Logistic regression was used to determine associations between intracorporeal injection use and preoperative variables. RESULTS The 8-year self-assessment was completed by 368 (50.4%) men. Of these men 140 (38%) indicated prior or current intracorporeal injection use, with only 34 using intracorporeal injection at 8 years. Overall, 44% of the men were satisfied with intracorporeal injections. Reasons for discontinuation included dislike (47%), pain (33%), return of erection (19%), inefficacy (14%) and no partner (6%). Men trying intracorporeal injections had greater preoperative UCLA-PCI sexual function scores (75.2 vs 65.62, p = 0.00005) as well as greater decreases in this score at 3 months (p = 0.0002) and 2 years (p = 0.003). Higher preoperative sexual function scores were independently associated with the use of intracorporeal injections in a model adjusted for age, marital status, nerve sparing status and body mass index (OR 1.021, 95% CI 1.008-1.035). CONCLUSIONS Men pursuing intracorporeal injections have better baseline erectile function and experience greater deterioration in erectile function during the early postoperative period. Despite the high efficacy of injections, many men discontinue intracorporeal injections due to dislike or discomfort. Satisfaction rates for intracorporeal injections indicate their long-term role in restoring sexual function in men with post-prostatectomy erectile dysfunction.
Collapse
Affiliation(s)
- Vinay Prabhu
- Department of Urology, New York University School of Medicine, New York, New York 10016, USA
| | | | | | | | | |
Collapse
|
6
|
Hsiao W, Bennett N, Guhring P, Narus J, Mulhall JP. Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med 2010; 8:512-7. [PMID: 21054797 DOI: 10.1111/j.1743-6109.2010.02093.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Intracavernosal injection therapy (ICI) is a well-established second-line therapy used in the treatment of erectile dysfunction (ED). Controversy exists as to whether oral phosphodiesterase type 5 inhibitors (PDE5i) or injection therapy lead to higher satisfaction. AIM This study addressed ICI satisfaction in a modern cohort of patients in the PDE5i era. METHODS Patients on ICI for at least 6 months were included in our study. Patients were administered the International Index of Erectile Function (IIEF) at the initial visit. On subsequent visits, patients were administered the IIEF and the Erection Hardness Scale (EHS). MAIN OUTCOME MEASURES Study end points were change in baseline scores in the satisfaction domains (SD) of the IIEF, type of injection medication used, and predictors of satisfaction. Multiple logistic regressions were performed for predictors of satisfaction. RESULTS One hundred twenty-two patients met inclusion criterion. Mean time to follow-up was 25±12 months (range 6-106 months). Sixty-five percent of patients continued injections at the time of follow-up. When SD scores were examined, intercourse SD scores increased from 4.8±1.7 at baseline to 12.3±3.1 (P<0.01); overall SD scores increased from 4.1±1.8 to 7.2±2.0 (P<0.05). On multivariate analysis, predictors of satisfaction included older age (odds ratio [OR]=2.1), younger partner age (OR=2.5), clinically significant increase in the erectile function domain score (OR=3.1), and attainment of a "fully rigid" erection (EHS 4) (OR=6.8). CONCLUSIONS We have evaluated satisfaction in a modern cohort of ICI patients. While dropout rates are significant, for those patients who continue to inject, we have found high levels of satisfaction using the IIEF, the gold standard for evaluation of erectile function. On multivariate analysis, we found that older age, younger partner age, and fully rigid erections were predictors of increased satisfaction. ICI remains a robust second-line therapy in the treatment of ED even in the era of PDE5i.
Collapse
Affiliation(s)
- Wayland Hsiao
- Weill Cornell Medical College, Department of Urology, Center for Male Reproductive Medicine, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
7
|
Ryu IW, Yoon H, Shim BS, Park YY, Chung WS. Can the PDE5 Inhibitor Replace Intracavernosal Injection as a Method for Inducing a Penile Erection during the Evaluation of Erectile Dysfunction Using Penile Duplex Ultrasonography? Korean J Urol 2008. [DOI: 10.4111/kju.2008.49.7.641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- In Wook Ryu
- Department of the Urology, Ewha Womans University School of Medicine, Seoul, Korea
| | - Hana Yoon
- Department of the Urology, Ewha Womans University School of Medicine, Seoul, Korea
| | - Bong Suk Shim
- Department of the Urology, Ewha Womans University School of Medicine, Seoul, Korea
| | - Young Yo Park
- Department of the Urology, Ewha Womans University School of Medicine, Seoul, Korea
| | - Woo Sik Chung
- Department of the Urology, Ewha Womans University School of Medicine, Seoul, Korea
| |
Collapse
|
8
|
Krupski TL, Litwin MS. Medical and Psychosocial Issues in Prostate Cancer Survivors. Oncology 2007. [DOI: 10.1007/0-387-31056-8_107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Abstract
A wide variety of medications, devices, and surgical interventions are available to patients who have ED. These range from first-line oral agents to second-line therapy with injections or vacuum devices to third-line options, such as penile prosthesis implantation. In this article, we cover available treatments for erectile dysfunction, ranging from first-line to third-line therapies.
Collapse
Affiliation(s)
- William O Brant
- University of Colorado School of Medicine, P.O. Box 40,000, Vail, CO 81658, USA.
| | | | | |
Collapse
|
10
|
Stimmel GL, Gutierrez MA. Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression. CNS Spectr 2006; 11:31-7. [PMID: 16871136 DOI: 10.1017/s1092852900026742] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Sexual dysfunction is a frequently encountered comorbid condition in patients with many medical and psychiatric conditions, such as epilepsy and depression. Most depressed patients experience some type of sexual dysfunction, decreased sexual desire being the most common. The association of sexual dysfunction with epilepsy is less clear. Changes in sex hormone levels are common in patients with epilepsy and may be attributable to the disease or to antiepileptic drugs (AEDs). Sexual dysfunction associated with depression or epilepsy is generally treated according to standard guidelines for the management of sexual disorders, since data from special populations are not available. The most common forms of female sexual dysfunction are lack of sexual desire and difficulty achieving orgasm. There are no approved pharmacotherapies for female hypoactive sexual desire disorder or female orgasmic disorder. Female sexual arousal disorder is treated with estrogen replacement therapy when indicated or vaginal lubricants. The most common male sexual dysfunction disorders are premature ejaculation and erectile dysfunction. Phosphodiesterase type-5 inhibitor drugs are now the first-line treatment for erectile dysfunction, and selective serotonin reuptake inhibitors and topical anesthetic creams are nonapproved but effective treatments for premature ejaculation. Testosterone and aromatase inhibitors have been used investigationally to treat sexual dysfunction in men taking AEDs. Patient education and follow-up appointments are essential to ensure optimal outcomes of pharmacologic treatments for sexual dysfunction.
Collapse
Affiliation(s)
- Glen L Stimmel
- University of Southern California, School of Pharmacy, Los Angeles, CA90089-9121, USA.
| | | |
Collapse
|
11
|
Ardicoglu A, Kocakoc E, Yuzgec V, Bozgeyik Z, Canatan H, Kiris A. Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. Int Urol Nephrol 2006; 37:785-9. [PMID: 16362600 DOI: 10.1007/s11255-005-3621-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Erectile dysfunction (ED) is one of the most encountered male health problem and sildenafil citrate is used worldwide for treatment of ED. Aim of the present study was to determine and evaluate hemodynamic effects of sildenafil citrate on segmental branches of bilateral renal arteries of cases with ED. PATIENTS AND METHODS Total of 35 male patients aging between 34 and 56 years were recruited into study. Patients were evaluated with renal color Doppler sonography (CDS) before and after (45-75 min) peroral sildenafil citrate (50 mg) administration. Peak systolic flow rate (V(max)), end diastolic flow rate (V(min)), resistive index (RI) and pulsatility index (PI) of renal artery segmental branches were determined before and after sildenafil citrate administration. RESULTS V(min) measured at right lower segment was significantly reduced after sildenafil administration (p = 0.030). Accordingly mean RI and PI of right lower segment of renal artery slightly increased after drug administration (p = 0.007 and p = 0.012, respectively). The measurements on other segments had no significant change after sildenafil treatment when compared to baseline values. On this single dose administration no side effect was recorded. CONCLUSION Findings of the present study demonstrated that peroral sildenafil citrate usage had slight effects on hemodynamic parameters of lower segmental branch of right renal artery. This result could not be interpreted as robust evidence for hemodynamic changes of renal arteries associated with sildenafil usage nevertheless warrants more comprehensive research with larger number of patients.
Collapse
|
12
|
Archer SL, Gragasin FS, Webster L, Bochinski D, Michelakis ED. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. Drugs Aging 2006; 22:823-44. [PMID: 16245957 DOI: 10.2165/00002512-200522100-00003] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The historical basis for understanding erectile function as a neurovascular phenomenon and the advance from fanciful to effective treatment of erectile dysfunction (ED) are reviewed, with emphasis on patients with cardiovascular disease (CVD). ED occurs in 60% of CVD patients by 40 years of age. Male ED and female sexual dysfunction (FSD) diminish quality of life and often warn of occult CVD. ED is often unrecognised but is readily diagnosed during a 5-minute interview using a truncated International Index of Erectile Function questionnaire. Erection of the penis and clitoral engorgement result from local, arousal-induced release of neuronal and endothelial-derived nitric oxide (NO). Arterial vasodilatation and relaxation of cavernosal smooth muscle cells cause arterial blood to flood trabecular spaces, compressing venous drainage, resulting in tumescence. Cyclic guanosine monophosphate (cGMP)-induced activation of protein kinase G mediates the effects of NO by enhancing calcium sequestration and activating large-conductance, calcium-sensitive K+ channels. Future treatment strategies will likely enhance these pathways. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil and vardenafil) increase cGMP levels in erectile tissue. These agents are effective in 80% of CVD patients with ED and can be used safely, even in the presence of stable coronary disease or congestive heart failure, provided nitrates are avoided and patients do not have hypotension, severe aortic stenosis or evocable myocardial ischaemia. Second-line therapies (vacuum constrictor device and transurethral or intracavernosal prostaglandin E1) can also be used in CVD patients. Treatment of FSD and its relationship to CVD are less well established, but similarities to ED exist. ED can be prevented by reduction of CVD risk factors, exercise, weight loss and abstinence from smoking.
Collapse
Affiliation(s)
- Stephen L Archer
- Department of Medicine Cardiology, University of Alberta, Edmonton, Alberta, Canada.
| | | | | | | | | |
Collapse
|
13
|
Munarriz R, Kim NN, Goldstein I, Traish AM. Erectile Dysfunction. Vasc Med 2006. [DOI: 10.1016/b978-0-7216-0284-4.50034-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
El-Sakka AI. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res 2005; 18:180-5. [PMID: 16163370 DOI: 10.1038/sj.ijir.3901388] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We have investigated the reliability of intracavernosal prostaglandin E1 (PGE1) office vs self-injection therapy in patients with erectile dysfunction (ED). A total of 298 male patients with ED were enrolled in this study. In all patients, intracavernosal titration of the PGE1 dose was performed. A total of 106 patients were enrolled in the self-injection program, and 192 patients were enrolled in the office injection program. There were significant differences between number of injections and amount of PGE1 per month, total number of injections, and total amount of PGE1 on office and self-injection programs (P < 0.05 for each). There was a significant increase in the dropout rate in the office injection group compared with the self-injection group (P < 0.05). There was an increase in penile fibrosis in the self-injection program compared with the office program (P < 0.05). A self-injection program is reliable. Office injection program can be reserved for a subset of ED patients with special preferences.
Collapse
Affiliation(s)
- A I El-Sakka
- Department of Urology, School of Medicine, Suez Canal University, Ismailia, Egypt.
| |
Collapse
|
15
|
Kocakoc E, Ardicoglu A, Bozgeyik Z, Kiris A, Yuzgec V, Ogur E. Effects of sildenafil on major arterial blood flow using duplex sonography. JOURNAL OF CLINICAL ULTRASOUND : JCU 2005; 33:173-175. [PMID: 15856513 DOI: 10.1002/jcu.20113] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
PURPOSE Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Oral use of sildenafil citrate is effective in the treatment of ED. Although the effects of sildenafil citrate have been investigated in several systems, its effect on aortic, superior mesenteric (SMA), and carotid artery blood flow is still unclear. The aim of this study is to investigate the early phase effects of sildenafil citrate on aortic, SMA, and carotid artery blood flow using color duplex sonography (CDS). METHODS Thirty-four patients with ED (aged 19-71) were included in this study. Peak systolic velocity, end diastolic velocity, and resistance index (RI) in aorta, SMA, and bilateral common and internal carotid arteries were measured at baseline and 45-75 minutes after the administration of sildenafil citrate using CDS. RESULTS Statistically significant changes were observed in only 3 of 18 parameters: an increase in post drug values of bilateral internal carotid artery peak systolic velocity (Vmax) compared to baseline values and a significant decrease in the RI value of the left main carotid artery after drug administration compared to baseline values. CONCLUSIONS Sildenafil citrate had no significant effect on aortic and SMA circulation and only caused mild changes in the carotid artery circulation. Although these alterations may be considered clinically insignificant, further studies assessing long-term effects of sildenafil are warranted.
Collapse
Affiliation(s)
- Ercan Kocakoc
- Department of Radiology, Firat University, Faculty of Medicine, Elazig, Turkey
| | | | | | | | | | | |
Collapse
|
16
|
Frajese G, Pozzi F. New achievements and pharmacotherapeutic approaches to impotence in the elderly. Aging Clin Exp Res 2003; 15:222-33. [PMID: 14582685 DOI: 10.1007/bf03324503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Erectile dysfunction (ED) has a negative impact on the quality of life of elderly men, but impotence is not an absolute concomitant of aging. Aging changes influencing sexual function in men consist of a decreased capacity to reach arousal by imagination or view, fragility of erection, and an increase in the refractory period. These events may be part of the andropause syndrome, which includes a decrease in intellectual activity, fatigue, depression, decreases in body hair, lean body mass and bone mineral density, accompanied by an increase in weight. As a consequence, the overlap of aging processes, concurrent diseases and social situations to which elderly men are subject, results in the great variability reported in epidemiological studies. In the same way, the complex physiology of erection depends on the social, environmental, or physical context in which it occurs. New achievements in research on intracellular mechanisms of erection and on the neuroendocrinology of aging contribute to better understanding the pathophysiology of ED in the elderly. For example, testosterone declines with age with great interindividual variability, since other hormonal changes are also involved. What currently can be easily identified is the alteration of LH-testosterone feedback alterations, although hormone levels fall in the normal range. Nevertheless, the extent to which age-dependent decline in hormones leads to health problems that may affect the quality of life remains to be clarified. Several concepts on aging-related processes have been challenged, and conditions that were once accepted as physiologically age-related are now thought to lead to medical problems, but until now erectile dysfunction remains underreported, underdiagnosed, and undertreated, especially in the elderly. Nowadays, we are witnessing a rapid growth in available pharmacotherapies, from intracavernous injections of vasoactive drugs, to powerful new oral agents, with differing pharmacological dynamic and kinetic properties. New options for treatment are therefore possible, taking into account both the possibility of changing ineffective drugs and augmenting efficacy by means of synergistic associations. This rich generation of progress is certainly contributing to a better medical approach to sexuality in aging people.
Collapse
Affiliation(s)
- Gaetano Frajese
- Department of Internal Medicine, Roma Tor Vergata University, Roma, Italy.
| | | |
Collapse
|
17
|
Monga M, Rajasekaran M. Erectile dysfunction: current concepts and future directions. ARCHIVES OF ANDROLOGY 2003; 49:7-17. [PMID: 12647774 DOI: 10.1080/302-01485010290099408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Abstract
Major advances in science and medicine have led to improved understanding of the pathophysiology of erectile dysfunction. The development of reliable pharmacological therapy for erectile dysfunction has led to heightened awareness in the public and medical communities. This article reviews recent clinical advances and future research directions.
Collapse
Affiliation(s)
- M Monga
- Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA.
| | | |
Collapse
|
18
|
Guay AT, Spark RF, Bansal S, Cunningham GR, Goodman NF, Nankin HR, Petak SM, Perez JB. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract 2003; 9:77-95. [PMID: 12917096 DOI: 10.4158/ep.9.1.77] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
19
|
Abstract
Erectile dysfunction (ED) is a prevalent problem in the world and wreaks havoc on the psychosocial well-being of sufferers as well as partners. First-line treatment for ED is oral therapy, however, the currently available oral erectogenic agent is not uniformly successful and requires approximately 1 h to exert its effect. Apomorphine is a novel, oral erectogenic agent taken sublingually. It exerts its effect on hypothalamic centres involved in the triggering of the erection cascade. It dissolves rapidly and results in an erection in responders in approximately 20 min. By avoiding first pass metabolism through its sublingual administration, apomorphine avoids any significant interaction with food or other drugs. In trials in over 4000 subjects representative of the general ED population, beneficial effects were seen in a significant percentage of men. Its exact position in the market remains to be seen, however, its ability to permit spontaneous sexual relations will prove to be of significant benefit to many men.
Collapse
Affiliation(s)
- John P Mulhall
- Department of Urology, Loyola University Medical Center, Stritch School of Medicine, 2160 S. First Avenue, Maywood, IL 60153, USA.
| |
Collapse
|
20
|
Abstract
The introduction of new oral therapies has completely changed the diagnostic and therapeutic approach to erectile dysfunction. A panel of experts in this field have developed guidelines for clinical evaluation and treatment based on the review of available scientific information.
Collapse
Affiliation(s)
- Eric Wespes
- Hôpital Civil de Charleroi, Urology Department, Belgium
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
INTRODUCTION In the UK, an estimated 17-19% of men suffer from erectile dysfunction (ED). Until the introduction of sildenafil, the medical treatment of ED mainly depended on intracavernosal injections. The introduction of MUSE has generated interest, since it obviates the use of 'needles'. MUSE is an intra-urethral method of alprostadil (prostaglandin E1 analogue) administration. We investigated the safety and efficacy of MUSE in 100 patients. PATIENTS AND METHODS After confirming the diagnosis of ED, treatment was started with MUSE. Once we were satisfied that the patients could self-administer MUSE, they were discharged from our clinic. They were contacted six months later and asked to complete a questionnaire. RESULTS Only 35% of the 100 patients (aged 46-73 years) with ED of mixed aetiology were initially successfully treated with MUSE. All but two of them needed 1,000 microg. After six months, only 43% of these initially successfully treated patients continued to use MUSE; of these, 33% only found it effective on every third occasion, or worse. The remaining 57% of the initially successfully treated patients stopped taking MUSE because it was no longer effective or it caused side-effects (such as urethral bleeding and/or irritation). DISCUSSION MUSE, in our experience, is moderately effective in treating ED. However, MUSE is an alternative in some patients with ED who do not respond to other treatments or where these options are contraindicated. Owing to the high dropout rate, patients treated with MUSE should be followed-up closely.
Collapse
Affiliation(s)
- M A Khan
- Department of Urology, Royal Free and University College Medical School (University College London), The Royal Free Hampstead NHS Trust, UK.
| | | | | | | |
Collapse
|
22
|
Rajasekaran M, Pagnon V, Monga M. Vasoactive agents induce cytotoxicity in cultured human penile smooth muscle cells. Urology 2002; 59:155-8. [PMID: 11796314 DOI: 10.1016/s0090-4295(01)01482-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVES To evaluate the direct in vitro cytotoxicity of vasoactive agents (papaverine, phentolamine, and prostaglandin E(1) [PGE(1)]) to human penile cavernosal smooth muscle cells. Intracavernous pharmacotherapy with vasoactive agents for male erectile dysfunction has been associated with long-term complications such as a reduction in penile smooth muscle content and fibrosis. METHODS Human penile cavernosal tissue explants (1 to 2 mm(3) size) were obtained with proper institutional review board approval from patients undergoing penile prosthesis implantation. Primary culture was initiated in Dulbecco's modified Eagles medium containing 10% fetal bovine serum, and monolayer cavernosal cells were grown in 48-well tissue culture dishes. At 60% to 80% confluence, cells were labeled overnight with (51)Na(2)CrO(4) (1.5 microCi) and then incubated with therapeutic concentrations of papaverine (1.5 to 30 mg/mL), phentolamine (0.5 mg/mL), and PGE(1) (5 microg/mL) alone, as well as in combination, for 30 minutes at 37 degrees C. At the end of incubation, an aliquot of supernatant was collected in scintillation vials. The release of cell-free chromium in supernatants was determined in a liquid scintillation counter, and results were expressed as the percentage of cytotoxicity. RESULTS Papaverine induced a significant dose-dependent increase in chromium release from the cavernosal cells. At therapeutic concentrations, papaverine (30 mg/mL) produced up to 60% cytotoxicity; PGE(1) (5 microg/mL) resulted in 40% toxicity. The combination of papaverine with either PGE(1) or phentolamine had a cumulative toxic effect, and maximal toxicity (70%) was observed with the triple combination. CONCLUSIONS Papaverine-induced cytotoxicity to cavernosal smooth muscle cells may contribute to the fibrosis and loss of smooth muscle content associated with the intracavernous pharmacotherapy. Quantitative evaluation of in vitro cytotoxicity in human cavernosal smooth muscle cell culture may be important in the development of new intracavernosal vasoactive agents.
Collapse
Affiliation(s)
- Mahadevan Rajasekaran
- Division of Urology, University of California, San Diego, School of Medicine, San Diego, California 92037-8897, USA
| | | | | |
Collapse
|
23
|
Seo KK, Kim SC, Jun IO, Oh MM, Lee MY. Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents. BJU Int 2001; 88:596-601. [PMID: 11678758 DOI: 10.1046/j.1464-4096.2001.02388.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate which vasoactive agents have synergistic effects on the cavernosal smooth muscles of rabbits and rats when the agents are combined with sildenafil. MATERIALS AND METHODS Relaxation responses of cavernosal smooth muscle to single agents (phentolamine, moxisylyte, sodium nitroprusside, forskolin, vasoactive intestinal peptide, VIP, papaverine and sildenafil) in the rabbit, and prostaglandin-E1 and sildenafil in the rat, and to combinations of each agent plus sildenafil, were assessed in vitro. The response to sildenafil of the rabbit strips with and without incubation with l-arginine (1 mmol/L) for 20 min was also evaluated. The effective concentrations for a half-maximal response of single agents and combination solutions were compared. RESULTS All single agents induced concentration-dependent relaxation of the rabbit and rat cavernosal smooth muscles. There was significant synergism on rabbit cavernosal smooth muscle when the sildenafil was combined with forskolin, sodium nitroprusside, VIP or phentolamine. There was also significant synergism with sildenafil plus prostaglandin-E1 in rat cavernosal muscles. There were no synergistic effects of combinations of sildenafil plus moxisylyte, papaverine or l-arginine. CONCLUSIONS These results suggest potentially effective combined therapies of sildenafil and intraurethral or intracavernosal prostaglandin-E1, intracavernosal forskolin or VIP, or oral phentolamine for patients with erectile dysfunction who have no success after monotherapy with these agents.
Collapse
Affiliation(s)
- K K Seo
- Department of Urology and Physiology, College of Medicine, Chung-Ang University, Seoul, Korea
| | | | | | | | | |
Collapse
|
24
|
Sahin M, Başar MM, Bozdoğan O, Atan A. Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental study. Urology 2001; 58:487-92. [PMID: 11549511 DOI: 10.1016/s0090-4295(01)01211-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To evaluate the short-term effects of different intracavernosal agents and to investigate the antifibrotic effect of verapamil combined with these intracavernosal agents. METHODS Forty-five Sprague-Dawley rats weighing 400 to 500 g each (mean weight 435.27 +/- 13.65 g) were equally divided into nine groups (n = 5). Papaverine (group 1), alprostadil (group 2), sodium nitroprusside (group 3), and verapamil (group 4) were injected alone intracavernously in 0.2-mL doses. Verapamil combined with papaverine, alprostadil, and sodium nitroprusside in 0.2-mL doses (0.1 mL verapamil and 0.1 mL vasoactive agent) were injected in groups 5 through 7. Group 8 was kept as a control group without injection, and isotonic saline alone was injected in group 9 during the same period. The intracavernous injection was done twice weekly with a 4-day interval. At the end of the study, total penectomy and multiple liver biopsies were performed to evaluate the histopathologic effects of the vasoactive agents and to test the liver function. RESULTS In all groups, the structure of the corpora cavernosa was well preserved generally and appeared similar to the control tissue. However, localized edema, fibrosis, macrophage infiltration, and polymorphonuclear leukocytes were found only at the injection site. Although these findings were not different from the findings in the saline and alprostadil groups, they were slightly more extensive in the papaverine and sodium nitroprusside alone groups and also in the vasoactive agent plus verapamil groups. Although mononuclear lymphocyte infiltration was found in the portal areas, advancing into the liver parenchyma, the liver function tests were within normal limits. CONCLUSIONS We observed that intracavernous injection, except with nitroprusside, caused focal intracavernosal fibrosis and edema. We believe these effects might not be caused by just the drug, but also by needle trauma, since general fibrosis was not observed in the short term. However, nitroprusside has a severe fibrotic effect on cavernosal tissue in the short term. Moreover, intracavernous verapamil injection could not prevent the fibrosis in the short term.
Collapse
Affiliation(s)
- M Sahin
- Department of Urology, Erzincan State Hospital, Erzincan, Turkey
| | | | | | | |
Collapse
|
25
|
Mulhall JP, Jahoda AE, Ahmed A, Parker M. Analysis of the consistency of intraurethral prostaglandin E(1) (MUSE) during at-home use. Urology 2001; 58:262-6. [PMID: 11489714 DOI: 10.1016/s0090-4295(01)01164-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
OBJECTIVES To determine the consistency of a successful response to intraurethral prostaglandin E(1) (MUSE), an effective treatment for a proportion of patients with erectile dysfunction, during at-home use in men who had a successful response in the office, to define the factors that correlated with the consistency of the response, and to determine whether patients continued long-term use. METHODS The study group consisted of men with documented erectile dysfunction who had a successful response (grade 3 or 4 erection) to MUSE during an initial in-office dose. All enrollees completed a home diary assessing the treatment success during at least five medication administrations. Factors such as patient age, vascular risk factor status, and degree of in-office response were prospectively evaluated as correlates of response consistency. Finally, patient follow-up was conducted in an attempt to define how many patients were continuing to use this medication as a long-term treatment modality. RESULTS Two hundred twelve patients underwent screening and 72 (34%) patients had in-office success. The overall per patient at-home consistency rate was 51%. None of the aforementioned factors correlated with the consistency of the response. At a mean of 9 months after beginning treatment, only 31% of the in-office responders were continuing to use MUSE. CONCLUSIONS Although MUSE is an appropriate and safe treatment for many patients with erectile dysfunction, the lack of consistency is a significant consideration. Clinicians should pay close attention to patient education in an effort to promote realistic expectations for MUSE therapy. Furthermore, the lack of consistency may significantly lower the patient's interest in continuing this treatment long term.
Collapse
Affiliation(s)
- J P Mulhall
- Department of Urology, Loyola University Medical Center, Maywood, Illinois 60304, USA
| | | | | | | |
Collapse
|
26
|
Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev 2001; 22:342-88. [PMID: 11399748 DOI: 10.1210/edrv.22.3.0430] [Citation(s) in RCA: 128] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
This review is designed to help the reproductive endocrinologist integrate his or her professional activity with those of other disciplines including urology, radiology, neurology, and psychology in order to successfully manage all of the inseparable aspects of male sexual and reproductive functioning. Significant advances in the field of male sexual physiology and pathophysiology and new methods of investigation and treatment of male sexual disorders are outlined. The review synthesizes available data on the following: norms of sexual organs, aging and sexuality, role of central and peripheral neurochemicals in each stage of the sexual cycle, role of corporeal smooth muscles in the hemodynamic control of erection and detumescence, influence of psychological factors, drugs, and disease on all aspects of sexual functioning, and use of nocturnal penile tumescence monitoring, imaging investigations, and neurophysiologic studies in the diagnostic workup of males with sexual dysfunction. Clinical algorithms are presented where appropriate. Extensive discussions on newly developed strategies in psychological and behavioral counseling, drug therapy, tissue engineering, nonsurgical devices, and surgical treatments for all forms of sexual disorders are also provided. Lastly, the effect of sexual dysfunction and its treatment on quality of life in affected men is addressed, along with recommendations for future research endeavors.
Collapse
Affiliation(s)
- F R Kandeel
- The Leslie and Susan Gonda (Goldschmied) Diabetes and Genetic Research Center, Department of Diabetes, Endocrinology & Metabolism, City of Hope National Medical Center, Duarte, California 91010, USA. fkandeel.coh.org
| | | | | |
Collapse
|
27
|
Beal K, Mears JG. Short report: penile lymphoma following local injections for erectile dysfunction. Leuk Lymphoma 2001; 42:247-9. [PMID: 11699217 DOI: 10.3109/10428190109097700] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We report a case of high grade lymphoma which appeared at the site of prior injections of medications into the shaft of the penis for erectile dysfunction. We discuss the possible mechanisms of causation for this unusual form of lymphoma.
Collapse
Affiliation(s)
- K Beal
- Columbia University College of Physicians and Surgeons, New York, NY, USA
| | | |
Collapse
|
28
|
|
29
|
Baçar MM, Batislam E, Altinok D, Yilmaz E, Baçar H. Sildenafil citrate for penile hemodynamic determination: an alternative to intracavernosal agents in Doppler ultrasound evaluation of erectile dysfunction. Urology 2001; 57:623-6; discussion 626-7. [PMID: 11306361 DOI: 10.1016/s0090-4295(01)00923-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVES To suggest a new noninvasive method for penile Doppler ultrasound (PDU) evaluation of erectile dysfunction using oral sildenafil citrate as an erection induction agent. METHODS A total of 20 patients admitted with the complaint of erectile dysfunction were evaluated by the short form of the International Index of Erectile Function. A total score of less than 25 was accepted as erectile dysfunction and PDU was performed. The initial penile study consisted of PDU examination under visual sexual stimulation (VSS), and the peak systolic velocity, end-diastolic velocity, and resistance index were recorded. Measurements of all the parameters were repeated on the same patients after intracavernosal papaverine, intracavernosal prostaglandin E(1) (PGE(1)), and oral sildenafil citrate administration, plus VSS. All patients had these four tests in the same order at weekly intervals. Sildenafil citrate was given orally 45 minutes before Doppler investigation, and patients had VSS during the waiting period. The patients were asked about their satisfaction and comfort after each test. Statistical analysis was performed using the Wilcoxon and Mann-Whitney U tests. RESULTS The measurements with papaverine, PGE(1), and sildenafil citrate were significantly different from those after only VSS (P <0.008); however, the papaverine, PGE(1), and sildenafil citrate results were not different from each other according to the peak systolic velocity, end-diastolic velocity, and resistance index measurements (P >0.008). Patients commented that although PGE(1) was the strongest erectogenic agent, sildenafil citrate was the most convenient. CONCLUSIONS Since the results of PDU with oral sildenafil citrate in association with VSS were not statistically different, we suggest a new noninvasive erection induction method for the purpose of PDU evaluation of erectile dysfunction.
Collapse
Affiliation(s)
- M M Baçar
- Department of Urology, University of Kirikkale Faculty of Medicine, Ankara, Turkey
| | | | | | | | | |
Collapse
|
30
|
Usta MF, Erdoğru T, Tefekli A, Köksal T, Yücel B, Kadioğlu A. Honeymoon impotence: psychogenic or organic in origin? Urology 2001; 57:758-62. [PMID: 11306399 DOI: 10.1016/s0090-4295(00)01057-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVES Honeymoon impotence is the inability to perform successful sexual intercourse during the initial experience, especially during the first nights of marriage, and it is relatively frequent in Turkey. We investigated the underlying penile vascular abnormalities in patients presenting with honeymoon impotence and sought to differentiate between psychogenic and organic etiologies. METHODS Between 1989 and 1999, 90 patients sought urologic help for honeymoon impotence. Patient age ranged from 18 to 39 years (mean 28.06 +/- 3.4). All patients were given an intracavernous injection of 60 mg papaverine combined with self-manual genital stimulation (CIS test) to assess the degree of tumescence. Patients with a positive response to the CIS test were later evaluated with nocturnal penile tumescence (NPT) monitoring. Patients with a negative response to the CIS test and/or NPT monitoring were evaluated further using penile color Doppler ultrasound. RESULTS A psychogenic etiology was found in 61 patients (67.7%), 50 (55.5%) of whom achieved satisfactory sexual intercourse after intracavernous injection. Twenty-five patients (27.7%) exhibited penile vascular abnormalities by color Doppler ultrasound. Neurogenic erectile dysfunction was considered in the remaining 4 patients (4.4%) with a positive response to the CIS test, abnormal findings on NPT monitoring, and a normal vascular system with color Doppler ultrasound. CONCLUSIONS The present study is the first to report penile vascular abnormalities in patients presenting with honeymoon impotence, which was previously believed to be exclusively psychogenic in origin. The evaluation of the penile vascular system in patients with honeymoon impotence may reveal underlying penile vascular abnormalities, allowing the choice of the appropriate therapeutic option.
Collapse
Affiliation(s)
- M F Usta
- Department of Urology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | | | | | | | | | | |
Collapse
|
31
|
MANIAM PRAKASH, SEFTEL ALLEND, CORTY ERICW, RUTCHIK SCOTTD, HAMPEL NEHEMIA, ALTHOF STANLEYE. NOCTURNAL PENILE TUMESCENCE ACTIVITY UNCHANGED AFTER LONG-TERM INTRACAVERNOUS INJECTION THERAPY. J Urol 2001. [DOI: 10.1016/s0022-5347(05)66538-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- PRAKASH MANIAM
- From the Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland and Center for Marital and Sexual Health, Beachwood, Ohio, and School of Humanities and Social Sciences, Penn State Erie, Behrend College, Erie, Pennsylvania
| | - ALLEN D. SEFTEL
- From the Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland and Center for Marital and Sexual Health, Beachwood, Ohio, and School of Humanities and Social Sciences, Penn State Erie, Behrend College, Erie, Pennsylvania
| | - ERIC W. CORTY
- From the Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland and Center for Marital and Sexual Health, Beachwood, Ohio, and School of Humanities and Social Sciences, Penn State Erie, Behrend College, Erie, Pennsylvania
| | - SCOTT D. RUTCHIK
- From the Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland and Center for Marital and Sexual Health, Beachwood, Ohio, and School of Humanities and Social Sciences, Penn State Erie, Behrend College, Erie, Pennsylvania
| | - NEHEMIA HAMPEL
- From the Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland and Center for Marital and Sexual Health, Beachwood, Ohio, and School of Humanities and Social Sciences, Penn State Erie, Behrend College, Erie, Pennsylvania
| | - STANLEY E. ALTHOF
- From the Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland and Center for Marital and Sexual Health, Beachwood, Ohio, and School of Humanities and Social Sciences, Penn State Erie, Behrend College, Erie, Pennsylvania
| |
Collapse
|
32
|
NOCTURNAL PENILE TUMESCENCE ACTIVITY UNCHANGED AFTER LONG-TERM INTRACAVERNOUS INJECTION THERAPY. J Urol 2001. [DOI: 10.1097/00005392-200103000-00023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Garg MK, Saini JS. PHARMACOLOGICAL THERAPY OF ERECTILE DYSFUNCTION. Med J Armed Forces India 2001; 57:47-51. [PMID: 27365579 PMCID: PMC4925039 DOI: 10.1016/s0377-1237(01)80091-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- M K Garg
- Classified Specialist (Medicine) & Endocrinology, Command Hospital (Southern Command), Pune-411040
| | | |
Collapse
|
34
|
HATZICHRISTOU DIMITRIOSG, APOSTOLIDIS APOSTOLOS, TZORTZIS VASILIOS, IOANNIDES EVANGELOS, YANNAKOYORGOS KONSTANTINOS, KALINDERIS ATHANASIOS. SILDENAFIL VERSUS INTRACAVERNOUS INJECTION THERAPY: EFFICACY AND PREFERENCE IN PATIENTS ON INTRACAVERNOUS INJECTION FOR MORE THAN 1 YEAR. J Urol 2000. [DOI: 10.1016/s0022-5347(05)67140-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- DIMITRIOS G. HATZICHRISTOU
- From the Department of Urology, School of Medicine and Center for Sexual Dysfunction, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - APOSTOLOS APOSTOLIDIS
- From the Department of Urology, School of Medicine and Center for Sexual Dysfunction, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - VASILIOS TZORTZIS
- From the Department of Urology, School of Medicine and Center for Sexual Dysfunction, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - EVANGELOS IOANNIDES
- From the Department of Urology, School of Medicine and Center for Sexual Dysfunction, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - KONSTANTINOS YANNAKOYORGOS
- From the Department of Urology, School of Medicine and Center for Sexual Dysfunction, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - ATHANASIOS KALINDERIS
- From the Department of Urology, School of Medicine and Center for Sexual Dysfunction, Aristotle University of Thessaloniki, Thessaloniki, Greece
| |
Collapse
|
35
|
SILDENAFIL VERSUS INTRACAVERNOUS INJECTION THERAPY: EFFICACY AND PREFERENCE IN PATIENTS ON INTRACAVERNOUS INJECTION FOR MORE THAN 1 YEAR. J Urol 2000. [DOI: 10.1097/00005392-200010000-00015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Affiliation(s)
- T F Lue
- University of California School of Medicine, San Francisco, USA.
| |
Collapse
|
37
|
Abstract
Erectile dysfunction is a common and distressing medical condition that is now highly amenable to treatment almost irrespective of the cause. Safe, non-surgical treatments with unequivocal efficacy are psychological therapy, intracorporeal injection of vasoactive drugs, transurethral vasodilators and oral sildenafil, all of which have been reported to have a 50-70% overall response rate. Vacuum constriction devices are acceptable for some, usually older patients and oral yohimbine is thought to have marginal efficacy. Local creams to induce or enhance erectile function are currently being investigated. There is no place for androgen supplementation unless the patient is profoundly hypogonadal. Treatment of hyperprolactinaemia is very effective but is a rare cause of erectile dysfunction. As intercourse may entail an unfamiliar level of physical activity, it is sensible to ensure that the patient is able to climb a flight or two of stairs comfortably without provoking undue breathlessness or chest pain and to provide suitable advice about technique before commencing treatment. Once it is clear to the patients that erectile dysfunction can be satisfactorily overcome, the long-term use of treatments to do so tends to wane. Thus, although the prospect of effective treatment for what had been for many a distressing life sentence has the potential to place new demands on the health service, there is no evidence that restrictions on prescribing will prove economically rational.
Collapse
Affiliation(s)
- A Levy
- University Research Centre for Neuroendocrinology, Bristol Royal Infirmary Division of Medicine, Southmead Hospital, Bristol, UK.
| | | | | |
Collapse
|
38
|
WESPES ERIC, SATTAR AHMEDA, NOËL JEANCHRISTOPHE, SCHULMAN CLAUDEC. DOES PROSTAGLANDIN E1 THERAPY MODIFY THE INTRACAVERNOUS MUSCULATURE? J Urol 2000. [DOI: 10.1016/s0022-5347(05)67901-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- ERIC WESPES
- From the Departments of Urology and Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels and Department of Urology, CHU Charleroi, Charleroi, Belgium
| | - AHMED A. SATTAR
- From the Departments of Urology and Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels and Department of Urology, CHU Charleroi, Charleroi, Belgium
| | - JEAN-CHRISTOPHE NOËL
- From the Departments of Urology and Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels and Department of Urology, CHU Charleroi, Charleroi, Belgium
| | - CLAUDE C. SCHULMAN
- From the Departments of Urology and Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels and Department of Urology, CHU Charleroi, Charleroi, Belgium
| |
Collapse
|
39
|
|
40
|
VARDI YORAM, SPRECHER ELLIOT, GRUENWALD ILAN. LOGISTIC REGRESSION AND SURVIVAL ANALYSIS OF 450 IMPOTENT PATIENTS TREATED WITH INJECTION THERAPY: LONG-TERM DROPOUT PARAMETERS. J Urol 2000. [DOI: 10.1016/s0022-5347(05)67902-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- YORAM VARDI
- From the Neurourology Unit, Rambam Medical Center and the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - ELLIOT SPRECHER
- From the Neurourology Unit, Rambam Medical Center and the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - ILAN GRUENWALD
- From the Neurourology Unit, Rambam Medical Center and the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| |
Collapse
|
41
|
|
42
|
Tan HL. Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. PHARMACOECONOMICS 2000; 17:77-107. [PMID: 10747767 DOI: 10.2165/00019053-200017010-00006] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
OBJECTIVE This paper examined the economic cost of male erectile dysfunction (ED) for a hypothetical managed-care (MC) model. DESIGN AND SETTING A prevalence-based cost-of-illness approach was used to estimate the direct medical cost for ED treatment. A treatment plan algorithm was developed from a MC perspective to model the initial treatment selection of various patient groups [vacuum erection device, intracavernosal injection (ICI) therapy, transurethral alprostadil suppository, sildenafil, testosterone replacement therapy, penile prosthesis] and their therapy outcomes during a 3-year period. Overall cost was based on 1998 US dollars. Total direct medical cost of ED considered in this model included the cost of initial physician consultation and evaluation, the cost incurred by patients from various treatment groups (pharmacological and surgical options), as well as the cost related to patients' follow-up for treatment within the 3-year period. Consideration for therapy switches made by patients who failed initial therapy was included as part of the clinical assumptions for this model. Treatment response and expected outcomes (dropouts) were considered for the various treatment options. PARTICIPANTS A total of 100,000 enrolled members were included in the study. MAIN OUTCOME MEASURES AND RESULTS The total cost of ED was $US3,204,792 for the 3-year period in the hypothetical MC plan. The treatment portion accounted for approximately 80% of the total cost while the cost of medical services and diagnostic tests were minimal in comparison. The 3 year total cost of nonsurgical treatment was $US2,473,045. Costs associated with each treatment alternative were $US81,866 (testosterone transdermal patch), $US51,930 (vacuum erection device), $US384,624 (ICI therapy), $US226,483 (transurethral alprostadil suppository) and $US1,728,142 (sildenafil citrate). Results from the model showed a noticeable trend of decreasing cost patterns over time and reflected the attrition observed for many of the standard medical therapies for ED. CONCLUSIONS Sildenafil and the vacuum erection device should be considered as first-line management strategies for ED whereas ICI therapy, transurethral alprostadil suppository and penile prosthesis implant should be reserved for second- or third-line therapy. Because costs associated with switches related to successive treatment failures can be high, treatment considerations should, therefore, focus on achieving long term patient satisfaction. The patient's preferred treatment choice, using goal-directed therapy during the initial consultation and evaluation visit, should be used.
Collapse
Affiliation(s)
- H L Tan
- Health Outcomes Research Design Consultants LLC, Dover, Delaware, USA.
| |
Collapse
|
43
|
Abstract
Erectile dysfunction (ED) is defined as the consistent inability to obtain or maintain an erection for satisfactory sexual relations. Data from the Massachusetts Male Aging Study have indicated that the prevalence of erectile dysfunction of any degree is 39% in 40-year old men, and 67% in those aged 70 years. Effective therapy has been available for some time, but it has commonly involved surgery, external devices or penile self-injection. For many men, these represent unacceptable barriers to seeking therapy. Recently, however, an effective oral medication has become available. This article reviews the physiology and pharmacology of ED. The literature currently available on the effectiveness and safety of various drugs used for ED is summarized, with particular attention to newly available oral agents. Guidelines for work-up and drug treatment of patients with ED are given. Detailed history and physical examination are crucial to the safe and effective treatment of men with erectile impotence. An extensive review of the literature shows that based on safety, effectiveness and ease of use, oral sildenafil citrate is an excellent choice for first-line therapy. Patients who use organic nitrates of any kind in any capacity should not be offered sildenafil. Based solely on effectiveness intracavernosal injection therapy remains the golden standard and should also be offered as an option for first-line therapy for the appropriate patients. Many alternatives are available for men who cannot use sildenafil or injection therapy. A thorough knowledge of existing medications is essential for proper treatment of ED.
Collapse
Affiliation(s)
- R G Manecke
- Department of Urology, Loyola University Medical Center, Maywood, IL 60657, USA
| | | |
Collapse
|
44
|
|
45
|
|
46
|
Nehra A, Barrett DM, Moreland RB. Pharmacotherapeutic advances in the treatment of erectile dysfunction. Mayo Clin Proc 1999; 74:709-21. [PMID: 10405703 DOI: 10.4065/74.7.709] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
An estimated 20 million to 30 million American men have erectile dysfunction (ED). The past 2 decades of research defining erectile physiology and investigating the pathogenesis of ED have led to the recognition of a predominantly vascular basis for organic male sexual dysfunction. These scientific advances have laid the foundation for the advent of pharmacotherapies. The Food and Drug Administration approval of intracavernosal, intraurethral, and oral pharmacotherapeutics for ED has revolutionized non-surgical management of this condition. The primary care physician is faced with the challenges of diagnosis and treatment of ED, as well as referral of patients to urologists. In this article, erectile physiology and pathophysiology are reviewed, and pharmacotherapeutics are classified and discussed by their mechanisms of action and the means of administration. A thorough understanding of these new therapeutic options is key to the accurate diagnosis and successful treatment of ED and maximal patient satisfaction and care.
Collapse
Affiliation(s)
- A Nehra
- Department of Urology, Mayo Clinic Rochester, Minn. 55905, USA
| | | | | |
Collapse
|
47
|
Spollett GR. Assessment and management of erectile dysfunction in men with diabetes. DIABETES EDUCATOR 1999; 25:65-73; quiz 75. [PMID: 10232182 DOI: 10.1177/014572179902500109] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE Erectile dysfunction occurs earlier in men with diabetes than in the general population, affecting over 50% of male patients by age 60. This article summarizes the etiologies and presents methods of patient assessment and treatment options for erectile dysfunction. METHODS Assessments of neurologic and vascular complications related to diabetes should be included in a sexual function history. The assessment must be holistic and focus on organic as well as psychogenic causes. Diabetes educators must be prepared to discuss the various pharmacologic treatment options. RESULTS Sildenafil currently is the only oral medication available for erectile dysfunction. Injectable treatments have proven successful but with limited long-term use and poor patient acceptance. Implantable devices carry surgical risk and increased rates of infection. CONCLUSIONS All men with diabetes should be screened for erectile dysfunction. The availability of a new oral medication provides a patient-acceptable treatment option.
Collapse
Affiliation(s)
- G R Spollett
- Yale University School of Nursing, New Haven, Connecticut, USA.
| |
Collapse
|
48
|
TREATMENT OF ERECTILE DYSFUNCTION AFTER KIDNEY TRANSPLANTATION WITH INTRACAVERNOSAL SELF-INJECTION OF PROSTAGLANDIN E1. J Urol 1998. [DOI: 10.1097/00005392-199806000-00041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159:1927-30. [PMID: 9598489 DOI: 10.1016/s0022-5347(01)63198-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
PURPOSE We evaluate the results of treatment of erectile dysfunction in kidney transplant patients with intracavernosal self-injection of vasoactive drugs. MATERIALS AND METHODS We evaluated and treated 26 male kidney transplant patients for erectile dysfunction. All patients had stable kidney function 6 to 75 months (mean 26.6 +/- 9) after transplantation. Each patient received an intracavernosal injection of 20 microg. prostaglandin E1 (PGE1), and after 20 to 30 minutes the response was assessed. Nonresponders received 40 microg. PGE1 at another visit, and those who showed no response were reinjected with 40 microg. PGE1 plus 30 mg. papaverine hydrochloride. A total of 21 patients were enrolled in a self-injection program and have been followed between 3 and 21 months (mean 11.6 +/- 2.7). RESULTS Hormonal alterations were seen in 7 patients with serum testosterone as low as 16.6 ng./ml. (normal 33 to 100), and testosterone injections gave only marginal response in 2. Intracavernosal injection of 20 microg. PGE1 provided good response in 15 patients (57.7%), while 40 microg. PGE1 alone or in combination with 30 mg. papaverine resulted in good response in another 6 and 2 patients, respectively. Among the 21 patients who were enrolled in the self-injection program 19 (90.5%) reported complete satisfaction with no adverse local or systemic complications except for local pain at the injection site in 4. There has been no change in serum creatinine, cyclosporine level or doses of immunosuppression medications during the observation period. CONCLUSIONS Intracavernosal self-injection of PGE1 is well accepted and tolerated by kidney transplant patients. It poses no apparent risks to the transplanted kidney and could be a good modality to treat erectile dysfunction in kidney transplant recipients.
Collapse
|
50
|
Foldvari M, Oguejiofor CJ, Wilson TW, Afridi SK, Kudel TA. Transcutaneous delivery of prostaglandin E1: in vitro and laser doppler flowmetry study. J Pharm Sci 1998; 87:721-5. [PMID: 9607949 DOI: 10.1021/js970425s] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The aim of this study was to assess the rate and extent of transcutaneous delivery of prostaglandin E1 (PGE1) from various formulations [liposomal, novel biphasic, and nonliposomal (oil/water cream) delivery systems] in vitro using diffusion cells and in vivo using laser doppler flowmetry, to aid in the development of a topically active preparation for the treatment of male sexual dysfunction. Percutaneous absorption through adult human foreskin was tested in flow-through diffusion cells using [3H]PGE1. Nine healthy volunteers participated in the crossover, randomized, double-blind, placebo-controlled study, where 0.1 g of each preparation was applied to a 4 cm2 area on the forearm. Laserflo BPM2 blood perfusion monitor with Model P-430 skin probe was used for evaluating skin blood perfusion. Encapsulation of PGE1 into novel biphasic delivery systems resulted in significantly increased skin blood perfusion relative to traditional liposomal, nonliposomal, and placebo formulations (6.25 +/- 1.58 vs 2.72 +/- 0.79, 0.53 +/- 0.64, and 0.58 +/- 0.06 mLLD/min/100 g, respectively, n = 9). The in vitro absorption of PGE1 through foreskin correlated well with the in vivo data (respective permeability coefficients 3.33, 1.57, and 1. 40 x 10(-4) cm/h). Formulation parameters greatly influence the absorption of PGE1 through skin as measured by laser doppler flowmetry, but by the application of a novel topical delivery technology, a significant enhancement of PGE1 delivery can be achieved.
Collapse
Affiliation(s)
- M Foldvari
- College of Pharmacy and Nutrition and Departments of Pharmacology, Surgery, and Medical Imaging, University of Saskatchewan, Saskatoon, SK, Canada S7N 5C9.
| | | | | | | | | |
Collapse
|